Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

178 results about "Bone cancer" patented technology

Abnormal growth that develops in the bone. It could be either cancerous or non-cancerous.

Ultrasound guided high intensity focused ultrasound treatment of nerves

A method for using high intensity focused ultrasound (HIFU) to treat neurological structures to achieve a desired therapeutic affect. Depending on the dosage of HIFU applied, it can have a reversible or irreversible effect on neural structures. For example, a relatively high dose of HIFU can be used to permanently block nerve function, to provide a non-invasive alternative to severing a nerve to treat severe spasticity. Relatively lower doses of HIFU can be used to reversible a block nerve function, to alleviate pain, to achieve an anesthetic effect, or to achieve a cosmetic effect. Where sensory nerves are not necessary for voluntary function, but are involved in pain associated with tumors or bone cancer, HIFU can be used to non-invasively destroy such sensory nerves to alleviate pain without drugs. Preferably, ultrasound imaging synchronized to the HIFU therapy is used to provide real-time ultrasound image guided HIFU therapy of neural structures.
Owner:UNIV OF WASHINGTON

Compositions and methods of use of targeting peptides for diagnosis and therapy

The compositions and methods include targeting peptides selective for tissue selective binding, particularly prostate and / or bone cancer, or adipose tissue. The methods may comprise targeting peptides that bind, for example, cell surface GRP78, IL-11Rα in blood vessels of bone, or prohibitin of adipose vascular tissue. These peptides may be used to induce targeted apoptosis in the presence or absence of at least one pro-apoptotic peptide. Antibodies against such targeting peptides, the targeting peptides, or their mimeotopes may be used for detection, diagnosis and / or staging of a condition, such as prostate cancer or metastatic prostate cancer.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Claudins as markers for early detection, diagnosis, prognosis and as targets of therapy for breast and metastatic brain or bone cancer

InactiveUS20050074798A1Decrease cell-to-cell adhesionPromote cell migrationPeptide/protein ingredientsMicrobiological testing/measurementCancer cellBacterial enterotoxins
Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed in the majority of breast cancers, and claudins 3 and 4 are overexpressed. The methods of treatment involve the use of Clostridium perfringens enterotoxin (or a variant thereof) to lyse metastatic cancer cells in the brain and bone that overexpress claudins 3 and 4.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

System for detecting bone cancer metastases

The invention relates to a detection system for automatic detection of bone cancer metastases from a set of isotope bone scan images of a patients skeleton, the system comprising a shape identifier unit, a hotspot detection unit, a hotspot feature extraction unit, a first artificial neural network unit, a patient feature extraction unit, and a second artificial neural network unit.
Owner:EXINI DIAGNOSTICS

Method of Treating Cancer and Bone Cancer Pain

InactiveUS20140179736A1Preventing bone metastasisImprove survivalBiocideNervous disorderMelanomaLung cancer
This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
Owner:EXELIXIS INC

Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof

This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.
Owner:PACIFIC ARROW

Bisphosphonate conjugates and methods of making and using the same

InactiveUS20050026864A1Promote bone growth bonePromote bone bone marrow proliferationBiocideSugar derivativesMedicineSoft Tissue Diseases
The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases and diseases of the soft tissues surrounding bones.
Owner:MBC PHARMA

Improved LF rotary and strong constant magnet field therapeutical instrument

InactiveCN1583193ARelieve or eliminate painImprove and increase densityMagnetotherapy using variable magnetic fieldsSide effectEngineering
An improved therapeutic appliance with strong and constant low-frequency rotary magnetic field for treating the late bone cancer and osteoporosis is composed of a drive structure consisting of vertical motor, belt, small and big belt wheels, two permanent magnets isolated by non-magnetic partition and a magnetic yoke, and a control unit consisting of infrared remote controller of motor, computer and printer.
Owner:杭州康尔医药科技有限公司

Nitroxides for use in treating or preventing neoplastic disease

Pharmaceutical compositions are provided that are useful in treating or preventing neoplastic disease, such as cancer. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cancer. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cancer. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cancer is esophageal cancer, hepatocellular carcinoma, colon cancer, prostate cancer, lung cancer, gastric carcinoma, renal cell carcinoma, bone cancer, breast cancer, cervical cancer, brain cancer, or a cancer associated with the tumor suppressor gene p53.
Owner:MATRIX BIOMED INC

Hydroxy phosphorite of near infrared fluorescence quantum point mark and its preparation process and application

A hydroxy apatite marked by the nanoparticles of near-infrared fluorescent quantum point for researching the growth of bone and diagnosing and treating the diseases, such as coronary sclerosis, bone cancer, etc is prepared by linking the nanoparticles of near-infrared fluorescent quantum point with the hydroxy opatite via adsorption, ion exchange, or covalent bonding.
Owner:TONGJI UNIV

Medicament capable of killing cancer cells and curing various tumors and cancers and leukemia

The invention relates to a medicament-tumor number 1 capable of killing cancer cells and curing various tumors and cancers and leukemia. The medicament comprises glossy ganoderma, ginseng, herba epimedii, astragalus membranaceus, giant knotweed rhizome, Chinese caterpillar fungus, heartleaf houttuynia herb and liquorice root. The medicament capable of killing cancer cells and curing various tumors and cancers and leukemia is prepared by pure traditional Chinese medicine, is good in treatment effects, less in side effects, short in treatment course and the like, is rapid in effect and high in cure rate, has effects of killing cancer cells and improving human body immunity, has functions of prolonging life and anti-aging and is capable of curing leukemia and various tumors and cancers, such as leukemia, bone cancer, lymphoma, intestinal cancer, liver cancer, renal carcinoma, gastric cancer, pelvic cancer, uterine cancer, cervical cancer, bladder cancer, prostatic cancer, pancreatic cancer, lung cancer, brain cancer, neuroendocrine tumor, mammary cancer and esophageal cancer.
Owner:陈玉堂

Novel use of niclosamide and pharmaceutically acceptable salt thereof

The invention discloses an application of niclosamide or pharmaceutically-acceptable salts thereof in preparing anti-tumor drugs, which provides a candidate drug for tumor patients and may further improve the therapeutic effect and the prognosis to patients. The effectiveness of niclosamide or pharmaceutically-acceptable salts thereof on various tumor cells indicates that the composition may be used for treating various cancers such as cerebroma, genitourinary tumor, lymphatic system, stomach cancer, cancer of larynx, nasopharyngeal cancer, skin cancer, bone cancer, leukaemia, leukaemia, breast cancer, histiocytic lymphoma, non-small-cell lung cancer, small-cell lung cancer, lung adenocarcinoma, epidermoid cancer, pancreatic cancer, prostatic cancer, liver cancer and epithelial cell cancer.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Antibodies, pharmaceutical compositions and methods

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.
Owner:OBI PHARMA

Method of prophylaxis

InactiveUS20040009955A1Heavy metal active ingredientsBiocideBiomedical engineeringMetastatic bone cancer
A method of prophylaxis of a subject having or having had a soft tissue cancer, whereby to combat metastatic bone cancer therein, the method comprising administering to said subject a physiologically tolerable polyphosphonate and, parenterally, a prophylactically effective amount of a soluble radium-223 or -224 salt or complex. A kit comprising a first container containing a soluble radium-223 or -224 salt or complex and a second container containing at least one dose of a physiologically tolerable polyphosphonate is also provided.
Owner:ALGETA AS

Biphosphonate conjugates and methods of making and using the same

The present invention is directed to particular bisphosphonate compounds, and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis.
Owner:MBC PHARMA

Osteoprotegerin variant proteins

InactiveUS20060189528A1Reduced binding affinityReduce capacityNervous disorderPeptide/protein ingredientsPAGET'S BONE DISEASEWild type
The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduce binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and / or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.
Owner:CEPHALON AUSTRALIA

Application of sugar-containing platinum complex in preparation of medicines for preventing and treating tumor

The invention discloses application of a sugar-containing platinum complex in the preparation of medicines for preventing and treating tumor. The sugar-containing platinum complex is shown as the formula (I). The test proves that the sugar-containing platinum complex shown as the formula (I) can prevent and treat cancer of mammals, such as lung cancer, colon cancer, head and neck cancer, prostatic cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoma, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, stomach cancer, male genital organ cancer, bone cancer and the like of the mammals, in particular can prevent and treat lung cancer, colon cancer, head and neck cancer, prostatic cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoma, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, stomach cancer, male genital organ cancer or bone cancer of human beings.
Owner:TIANJIN GUDUI BIOLOGICAL MEDICAL TECH INC

Application of compound as JAK-STAT3 signal passage inhibitor

The invention discloses an application of a compound as a JAK-STAT3 signal passage inhibitor, and particularly relates to an application of a compound with a formula I or pharmaceutically acceptable salt of the compound in the process of preparing an anti-tumor medicament. The application provides a novel treating candidate medicament for a tumor patient, thereby probably further improving the treatment effect on the patient and improving the prognosis of the patient. The compound with the formula I or the pharmaceutically acceptable salt of the compound has the effect on various tumor cells, which indicates that the compound can be used for treating various cancers including cerebral tumor, genitourinary system tumor, lymphatic system tumor, stomach cancer, laryngeal cancer, nasopharyngeal cancer, skin cancer, bone cancer, blood cancer, leukemia, breast cancer and histiocytic lymphoma, non-small cell lung cancer, small-cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, pancreatic cancer, prostatic cancer, liver cancer, epithelial cell cancer and the like. The definition of genes in the formula refers to description for details.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors

InactiveUS20100010009A1Improve efficacyDesirable pharmacokinetic propertyBiocideOrganic chemistryGingival diseaseChagas disease
The present invention relates to compounds of formula (1), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R1 and R2 is H, and the other is selected from F and Cl, or R1 and R2 are both F; R3 is selected from cyclopentyl and cyclohexyl; R4 is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.
Owner:GRUNENTHAL GMBH

Application of T-2 toxin in the preparation of drugs for treating bone cancers and myeloproliferative disorder

The invention discloses a new use of T-2 toxin, that is, application of T-2 toxin in the preparation of drugs for treating bone cancers and myeloproliferative disorder, wherein the curative dose thereof is 0.1-20 mg / Kg (weight), preferably 0.5-8 mg / Kg (weight), during drug administration, the method comprises oral administration, intravenous injection, hypodermic injection and intramuscular injection. The invention establishes animal or cell models of multiple myeloma, osteosarcoma and myelodysplastic syndrome, and inspects the inhibition of the T-2 toxin on the tumors or tumor cells by injection or cell co-culture. The experiment shows that the T-2 toxin is capable of inhibiting the growth of tumor cells and has good killing effect on the bone cancers and myeloproliferative disorder.
Owner:SHENZHEN ICARBONX INTELLIGENT PEPTIDE PHARM TECH CO LTD

1,2,5-oxadiazole derivative and purpose thereof

PendingCN109574950ASignificant indoleamine-2,3-dioxygenase inhibitory activityGood treatment effectSenses disorderNervous disorderDiseaseHead and neck tumors
The invention discloses a compound having the following general formula (I), wherein K is selected from a cycloalkane group shown in the following formula. The invention also discloses an indoleamine-2,3-dioxygenase inhibitor comprising the compound and an application of the compound in preparation of drugs for treating cancer. The compound of the invention can effectively inhibit cell proliferation, has a good therapeutic effect on various diseases such as cancer, has significant therapeutic effects on breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostatic cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, stage IV melanoma, glioma, glioblastoma, hepatocellular carcinoma, mastoid renal tumor, head and neck tumor, leukemia, lymphoma, myeloma, non-small cell lung cancer, and the like, and has very broad application prospects.
Owner:SHANGHAI SHENGYUE PHARM TECH CO LTD

CT Based Probabilistic Cancerous Bone Region Detection

A method of determining a boundary of a cancer of a bone of a patient includes imaging the patient's bone. A bone density ratio of interest may be obtained from the image of the bone, the bone density ratio of interest being a ratio of a first density of the bone at a first location in the image to a second density of the bone at a second location in the image. The obtained bone density ratio of interest may be compared to a reference bone density ratio of interest of a reference bone without bone cancer. Based on the comparison, it may be determined whether the cancer of the bone of the patient is present at the first location in the image or the second location in the image. The imaging may be CT imaging, and the imaging may include a first plurality of images in a first plane.
Owner:HOWMEDICA OSTEONICS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products